BioSpace News Archive

Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC).

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver Meeting in Boston on November 13, 2023.

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced the initiation of its Phase IIb clinical trial treating patients suffering from Tourette Syndrome (TS) with its SCI-110, proprietary drug candidate.

According to Vision Research Reports, the global digital therapeutics market size was surpassed at USD 3.91 billion in 2022 and is expected to hit around USD 25.32 billion by 2032, growing at a CAGR of 20.54% from 2023 to 2032.

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it will participate in the Jefferies London Healthcare Conference.

The global live cell imaging market size is estimated to garner around USD 5.74 billion by 2032 and is growing at a CAGR of 8.3% from 2023 to 2032.

The global radiopharmaceuticals market size is projected to surpass around USD 13.67 billion by 2032 from USD 5.2 billion in 2022 and is expanding at a CAGR of 10.2% between 2023 to 2032.

Partners STADA and Alvotech announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency has adopted a positive opinion for Uzpruvo, a biosimilar candidate to Stelara®.

Biotricity Inc. (Nasdaq:BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023.

Resonant, a subsidiary of Renew Biotechnologies aimed at releasing novel diagnostics for neurodegenerative diseases, recently published research revealing a novel blood biomarker of neurodegeneration.